Skip to main content

Table 1 LCMRglu in efferent brain regions of control and CRFR2-null mice in response to 5-HT 1A R or 5-HT 2 R agonist

From: Increased anxiety in corticotropin-releasing factor type 2 receptor-null mice requires recent acute stress exposure and is associated with dysregulated serotonergic activity in limbic brain areas

 

Control

CRFR2-null

Control

CRFR2-null

 

Saline

8-OH-DPAT

%

Saline

8-OH-DPAT

%

Saline

DOI

%

Saline

DOI

%

Neocortex

            

Frontal

46 ± 3

33 ± 3*

−28

47 ± 3

42 ± 3*

−21 a

47 ± 3

38 ± 2*

−19

45 ± 2

30 ± 2*

−33 a, b

Anterior cingulate

48 ± 3

35 ± 2*

−27

49 ± 2

39 ± 4*

−35 a

50 ± 3

40 ± 2*

−15

51 ± 3

34 ± 2*

−33 a

Prefrontal

47 ± 3

35 ± 3*

−26

47 ± 3

42 ± 2

−6 a

50 ± 3

39 ± 3*

−22

50 ± 3

30 ± 2*

−40 a

Somatosensory

55 ± 2

33 ± 4*

−40

51 ± 4

45 ± 3*

−22 a

56 ± 2

53 ± 3

−5

55 ± 4

44 ± 3*

−20 a

Parietal

53 ± 2

35 ± 2*

−34

50 ± 4

43 ± 3

−21 a

55 ± 2

45 ± 1*

−18

54 ± 3

37 ± 2*

−31 a, b

Hippocampus

            

Subiculum

40 ± 3

26 ± 3*

−35

45 ± 3

23 ± 3*

−49 a

42 ± 2

43 ± 3

2

43 ± 3

33 ± 3*

−23

Dentate gyrus

26 ± 3

16 ± 3*

−38

30 ± 2

15 ± 3*

−50 a

28 ± 3

18 ± 2*

−36

27 ± 3

16 ± 2*

−14 a

CA1

37 ± 3

22 ± 4*

−41

38 ± 3

16 ± 2*

−58 a

36 ± 3

26 ± 3*

−28

37 ± 2

26 ± 2*

−30 a

CA2

35 ± 3

20 ± 3*

−43

36 ± 3

19 ± 2*

−47 a

35 ± 3

34 ± 3

−3

36 ± 3

29 ± 2*

−19

CA3

38 ± 2

20 ± 2*

−47

41 ± 2

17 ± 2*

−58 a

36 ± 2

28 ± 3

−22

36 ± 2

22 ± 3*

−39 a

Extrapyramidal areas

            

Medial striatum

43 ± 3

33 ± 2*

−23

42 ± 3

39 ± 3

−7 a

45 ± 3

34 ± 2*

−24

46 ± 3

29 ± 2*

−37 a

Lateral striatum

46 ± 3

29 ± 3*

−37

44 ± 3

41 ± 3

−7 c

46 ± 4

30 ± 3*

−35

48 ± 4

31 ± 3*

−35 a

Globus pallidus

33 ± 2

20 ± 2

−39

32 ± 2

33 ± 2

−3 a, b, c

32 ± 2

30 ± 2

−6

35 ± 2

23 ± 3*

−34 a, c

Substantia nigra

30 ± 3

20 ± 1*

−27

27 ± 3

25 ± 4

−7

28 ± 4

30 ± 2

7

28 ± 2

18 ± 4

−36

Limbic areas

            

Medial septal nucleus

41 ± 3

30 ± 2*

−27

39 ± 3

22 ± 2*

−44 a

45 ± 2

31 ± 2*

−31

48 ± 3

30 ± 2*

−38 a

Lateral septal nucleus

38 ± 3

27 ± 3*

−29

40 ± 2

18 ± 2*

−55 a, c

37 ± 3

28 ± 3

−24

40 ± 4

27 ± 3*

−33 a

Bed nucleus of the stria terminalis

27 ± 4

18 ± 2*

−33

31 ± 2

16 ± 3*

−48 a

30 ± 4

20 ± 2

−33

30 ± 2

18 ± 3*

−40 a

Basolateral amygdala

36 ± 3

26 ± 3*

−28

36 ± 2

15 ± 2*

−58 a, b, c

38 ± 2

27 ± 4

−29

38 ± 2

24 ± 4*

−37 a

Central amygdala

26 ± 2

20 ± 2*

−23

25 ± 3

15 ± 2*

−40 a

25 ± 2

17 ± 2

−32

24 ± 3

15 ± 2*

−38 a

  1. Local cerebral glucose utilization (LCMRglu), shown as mean ± SEM and percentage change in LCMRglu in 8-OH-DPAT or DOI compared with saline-treated mice. n = 8. aMain effect of drug; bmain effect of genotype, cgenotype X drug interaction in 2-way ANOVA, where critical F(1,28) value was 4.20 for P ≤ 0.05. *P < 0.05 vs saline in post-hoc analysis.